Review Reports

Round 1

Reviewer 1 Report

The manuscript by Quilbe et. al. reports an PDT treatment for pancreatic adenocarcinoma. The designed photosensitizer (PS-Fol/PS2) targeting the folate receptor with a high affinity, which shows promising results on mice model. This paper is suitable for publication in Journal of Clinical Medicine after minor revision.

It would be better to show the chemical structure of PS2. In line 217, “(C) Menbrane” should be membrane. Also, the figure 1C is missing. In Figure 3B, the y axis should use “4.0 x 10⁶ “ as an uniform format with other figures.

Author Response

please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

    The manuscript presents a well articulated experimental design and sound discussion of the achieved results to show the efficiency of photodynamic therapy for treatment of Pancreatic Adenocarcinoma. The in-vivo and in-vitro studies carried out by the authors show a clear indication that the use of the new generation photosensitizer for Photodynamic therapy can serve as effective treatment strategy against Pancreatic adenocarcinoma. Exhibition of the immune system activation by this treatment is of importance as most of the anti-cancer treatments tend to decrease the immune system in the patients. Further studies will be needed to translate this as a clinical treatment, but this study opened a new treatment avenue against Pancreatic Adenocarcinoma.

Author Response

Reviewer #2

The manuscript presents a well articulated experimental design and sound discussion of the achieved results to show the efficiency of photodynamic therapy for treatment of Pancreatic Adenocarcinoma. The in-vivo and in-vitro studies carried out by the authors show a clear indication that the use of the new generation photosensitizer for Photodynamic therapy can serve as effective treatment strategy against Pancreatic adenocarcinoma. Exhibition of the immune system activation by this treatment is of importance as most of the anti-cancer treatments tend to decrease the immune system in the patients. Further studies will be needed to translate this as a clinical treatment, but this study opened a new treatment avenue against Pancreatic Adenocarcinoma.

We would like to thank the reviewer for his support and positive and encouraging comments on our research work.

We are convinced of the benefits and contribution of PDT in the treatment of pancreatic adenocarcinoma. Our work continues in this direction and we hope that this first publication will serve as a springboard for our investigations.